share_log

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

Benzinga Real-time News ·  Aug 10, 2022 06:30
  • The U.S. Food and Drug Administration (FDA) has granted Fast Track designation toRelmada Therapeutics' (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading session at $27.25. The company shares are currently trading down 5 percent at $25.89 in the after-hours session.
  • ClearPoint Neuro (NASDAQ:CLPT) announced the U.S. Food and Drug Administration (FDA) 510(k) clearance to its Maestro Brain Model, intended for automatic labeling, visualization, volumetric and shape quantification of segmentable brain structures from a...
Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment